看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 4.4x - 4.9x | 4.6x |
| Historical Pb Multiple | 5.5x - 13.8x | 6.1x |
| Fair Value | $168.24 - $185.95 | $177.09 |
| Upside | 12.3% - 24.1% | 18.2% |
| Benchmarks | - | Full Ticker |
| Gilead Sciences, Inc. | - | NasdaqGS:GILD |
| BioMarin Pharmaceutical Inc. | - | NasdaqGS:BMRN |
| Regeneron Pharmaceuticals, Inc. | - | NasdaqGS:REGN |
| Vertex Pharmaceuticals Incorporated | - | NasdaqGS:VRTX |
| Novavax, Inc. | - | NasdaqGS:NVAX |
| CSL Limited | - | OTCPK:CMXH.F |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| GILD | BMRN | REGN | VRTX | NVAX | CMXH.F | |||
| NasdaqGS:GILD | NasdaqGS:BMRN | NasdaqGS:REGN | NasdaqGS:VRTX | NasdaqGS:NVAX | OTCPK:CMXH.F | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | -38.3% | NM- | 15.8% | NM- | NM- | 6.6% | ||
| 3Y CAGR | -57.4% | NM- | -18.2% | NM- | NM- | 3.6% | ||
| Latest Twelve Months | -91.5% | 154.6% | 11.6% | -114.8% | 65.6% | 11.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 12.3% | 13.5% | 38.3% | 30.3% | -105.3% | 20.7% | ||
| Prior Fiscal Year | 20.9% | 6.9% | 30.1% | 36.7% | -55.4% | 16.5% | ||
| Latest Fiscal Year | 1.7% | 15.0% | 31.1% | -4.9% | -27.5% | 17.9% | ||
| Latest Twelve Months | 1.7% | 15.0% | 31.1% | -4.9% | -27.5% | 18.0% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 16.3% | 7.0% | 28.6% | 23.5% | -613.5% | 21.9% | ||
| Prior Fiscal Year | 25.7% | 3.5% | 16.3% | 23.0% | NM | 14.5% | ||
| Latest Twelve Months | 2.3% | 8.0% | 16.0% | -3.2% | NM | 15.4% | ||
| Next Fiscal Year | 45.8% | 14.1% | 16.2% | 25.8% | 18.7% | 17.3% | ||
| Two Fiscal Years Forward | 38.8% | 15.4% | 16.6% | 24.1% | -2.3% | 17.6% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 4.6x | 4.0x | 4.3x | 11.1x | 1.5x | 4.9x | ||
| Price / LTM EPS | 278.3x | 26.9x | 13.9x | -227.6x | -5.4x | 27.0x | ||
| Price / Book | 6.9x | 2.0x | 2.1x | 7.4x | -1.6x | 4.0x | ||
| Price / Fwd Book | 5.5x | 1.8x | 2.0x | 6.3x | -1.3x | 3.8x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -1.6x | 2.1x | 7.4x | |||||
| Historical P/B Ratio | 5.5x | 6.1x | 13.8x | |||||
| Selected P/B Multiple | 4.4x | 4.6x | 4.9x | |||||
| (x) Book Value | 18,559 | 18,559 | 18,559 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GILD | BMRN | REGN | VRTX | NVAX | CMXH.F | |
| Value of Common Equity | 133,563 | 11,496 | 61,373 | 121,878 | 1,004 | 72,566 | |
| (/) Shares Outstanding | 1,245.3 | 190.8 | 107.0 | 256.8 | 160.8 | 484.2 | |
| Implied Stock Price | 107.25 | 60.26 | 573.45 | 474.62 | 6.24 | 149.87 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 107.25 | 60.26 | 573.45 | 474.62 | 6.24 | 149.87 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |